Concord Biotech IPO GMP, Details to watch, Guidance & Subscription status @ Chanakyanipothi.com India`s Oldest & the most Trusted Investment website. Operational since 8th December 1999, this is the Only Investment website in India, which has successfully completed 23 Years.
Concord Biotech IPO listing Review: As compared to issue price of Rs. 741, the scrip listed at Rs. 900. Those who bought shares at the initial stage at GMP of 345, have incurred loss of Rs. 186 whereas those who bought shares recently are at profit of Rs. 37.
Concord Biotech IPO Listing Estimate:
Concord Biotech IPO received strong support from the QIBs due to its strong business and profitability. However due to uncertainty in the grey market, the retail response is not impressive. Since last two sessions, fancy in the grey market has improved. The scrip is expected to get listed at Rs. 880/890 as compared to the issue price of Rs. 741.
Concord Biotech IPO Guidance.
It is one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share. Shares are offered at reasonable valuation and leaves room for listing gains. Do apply.
Concord Biotech IPO Grey Market Premium
For latest updates of GMP, click
Subscription Status of Concord Biotech IPO?
On 8 August 2023 @ 5.00 (Day 3) (Closed)
Review: strong support from QIBs & HNIs
QIB: 37583331 Shares 67.67 T
NII(10L+): 18791666 Shares 19.30 T
NII (<10L) 9395834 Shares 12.37 T
NII (Total) 28187500 Shares 16.99 T
RII: 65770833 Shares 3.78 T
Emp: 1971153 Shares 24.47 T
Total: 133512817 Shares 24.86 T
Concord Biotech IPO Promoters
SUDHIR VAID AND ANKUR VAID
Concord Biotech IPO Company Details to watch
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2021, supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. The company commanded a market share of over 20% by volume in 2021 across identified fermentation-based API products, including dactinomycin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine. As of March 31, 2022, it had a total installed fermentation capacity of 1,250 m3.
In 2016, it launched its formulation business in India as well as emerging markets, including Nepal,
Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States.
Growth Potential: Concord Biotech is amongst the few companies globally that have successfully and sustainably established and scaled up fermentation-based API manufacturing capabilities. The global small-molecule fermentation-based API market was valued at US$11 billion (Rs. 817 billion) in 2021. The market is expected to reach approximately US$13 billion (Rs 966 billion) in 2026, representing a CAGR of 3.6% from 2021 to 2026. Growth of the fermentation-based API market is expected to be driven primarily by the therapeutic areas of immunology, oncology and anti-infectives.
It has an established presence in these therapeutic areas and are well-poised to benefit from the industry growth tailwinds. As of March 31, 2022, it had six fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It aims to continue to grow its immunosuppressant API portfolio, which will remain one of the key contributors to our API business in the near future. In addition to its immunosuppressant API portfolio, we aim to increase the sales of its APIs across other therapeutic areas. The company has invested significantly in capacity expansion in recent years. With its increased capacities, it is in the process of scaling up its API production to serve more customers.
As of March 31, 2022, it had 22 API products. It had filed more than 120 Drug Master Files (“DMFs”) across several countries for its APIs, including 20, 63 and four, respectively, in the United States, Europe and Japan.
In addition, it had obtained Certification of Suitability to the Monographs of the European Pharmacopoeia (“CEPs”) for 13 APIs as of March 31, 2022.
To capitalize on the benefits of backward integration that its presence in APIs provides, it entered into the formulations segment in 2016. In India, it markets a portfolio of 27 brands across immunosuppressants, nephrology drugs and anti-infective drugs for critical care.
For more information about the company, click www.concordbiotech.com
Objects of the IPO
This is only offer for sale.
Concord Biotech IPO Details to watch. | |
IPO opens on | 4 Aug ,2023 |
IPO closes on | 8 Aug ,2023 |
Issue Type | Book Built Issue IPO |
Issue Size | up to 20,925,652 Shares / Rs (?) Cr |
* Fresh Issue | N.A. |
* Offer for Sale | 20,925,652 Sh |
Employees Discount | 10000 Shares/Rs.70 |
Face Value per share: | Rs. 1 |
Price Band | Rs. 705-741 |
Employee discount | Rs. 0 per share |
Retail Lot Size | 20 Shares |
Listing will at | BSE, NSE |
Shares offered to | Shares | Rs. in Cr |
QIB (50 %) | 10457826 | 774.92 |
NII (15 %) | 3137348 | 232.48 |
RII (35 %) | 7320478 | 542.48 |
Employees | 10000 | 0.74 |
Total Shares | 20,925,652 | 1550.72 |
Retail portion will be oversubscribed by | (?) Forms | |
How much Shares to Apply? | Rs. | |
Min Retail Application | 20 Shares | 14820 |
Max Retail Application | 260 shares | 192660 |
Small HNI (Min) application | 280 Shares | 207480 |
Small HNI (Max) application | 1340 shares | 992940 |
Big HNI Application | 1360 shares | 1007760 |
Concord Biotech IPO Tentative timetable | |
IPO opens on | 4 Aug 2023 |
IPO Closes on | 8 Aug 2023 |
IPO Allotment on | 11 Aug 2023 |
Unblocking of ASBA | 14 Aug 2023 |
Credit to Demat Accounts | 16 Aug 2023 |
Listing on | 18 Aug 2023 |
Registered Office of Concord Biotech | |
1482-86, Trasad Road, Dholka, Ahmedabad – 382225, Gujarat, India | |
Concord Biotech IPO Lead Managers | |
Kotak Mahindra Capital, Jefferies India, Citi group Global Markets | |
Registrar to Concord Biotech IPO | |
Link Intime India Pvt. Ltd |
Concord Biotech IPO Financial & Analytical Ratios | ||||
Year | Total Income | Net Profit | EPS | RoNW |
Rs. in Cr. | Rs.in Cr. | Rs. | % | |
2020-21 | 630.75 | 234.89 | 22.45 | 26.55 |
2021-22 | 736.35 | 174.93 | 16.72 | 16.64 |
2022-23 | 888 | 240.00 | 22.95 | 20.06 |
Book Value of the Share on | 31.03.2023 | Rs.123.31 | ||
Book Value of the Share | after the IPO | Rs.123.31 | ||
Offer Price | Rs. 741 |
Ratio Analysis | |
Upper Price Band/last EPS | 32.29 |
Upper offer price/Book Value Ratio | – |
Upper offer price/BV after IPO Ratio | – |
Concord Biotech Peer Comparison
As on date of DRHP | Total | PE | RoNW |
Income | Ratio | ||
Rs. In Cr | of | % | |
The IPO Company | 853 | 32.29 | 20.06 |
Divi’s Lab | 7768 | 54.15 | 14.28 |
Suven Pharma | 1340 | 30.08 | 23.70 |
Laurus Lab | 6040 | 23.70 | 19.68 |
Shilpa Medicare | 1050 | NA | NA |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Concord Biotech IPO GMP Details to watch Guidance & Subscription
>>Go to Mainboard IPOs Section: Click
>>Go to SME IPOs Section: Click
>>Get Good Staff or Job, Click: Staffavailable.com
>>Interested in Used Automobiles or vintage cars? Click: BigGaddi.com
>>Get solid Guidance on Mutual fund Investments, Click: ChanakyaMFGuidance.com
>>Study Stock Research Reports, Click: AnalysisLibrary.com
>>Interested in Crossword Puzzles? Click: Magajmari.com
Apply for listing gain & long term portfolio stock call by anil singhvi zee business
Rare enterprise of Rakesh jhunjhunwala invested in 2004.price is high.MF and Anchor have invested.chance of allotment so one can invest for small premium. Long term just like mankind pharmacy.
– Company operates in API Manufacturing and formulations related API
– Majority off raw material is imported from China
-API contributes 90% revenue, formulations 10%
-revenue splits India -50%, USA -18%, Rest of the world -32%
HDFC MF, ICICI Pru, SBI MF have collectively invested 90 crs. This is over and about the Pre IPO in which Singapore based Amansa came in as investor and other secondary engagements which should interest from MIT Endowment Fund, Steadview, Malabar Investments amongst others.